{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:12:38Z","timestamp":1780722758164,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jcjd.2015.06.010","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T17:44:48Z","timestamp":1445708688000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"Bernard","family":"Zinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ahr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Neubacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2015.06.010_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015, a patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4158\/EP15693.CS","article-title":"Aace\/Ace comprehensive diabetes management algorithm 2015","volume":"21","author":"Garber","year":"2015","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.jcjd.2015.06.010_bib0020","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.jcjd.2013.01.021","article-title":"Pharmacologic management of type 2 diabetes","volume":"37","author":"Harper","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0025","series-title":"Guidelines Task Force. Global guideline for type 2 diabetes","author":"IDF Clinical","year":"2012"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2013.03.003","article-title":"Changes in time to insulin initiation in type 2 diabetes patients: A retrospective database analysis in Germany and UK (2005\u20132010)","volume":"7","author":"Kostev","year":"2013","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/dom.12075","article-title":"Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and\/or other diabetic medications: Results from INSPIRE ME IAA","volume":"15","author":"Smith","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs. other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/dc10-1318","article-title":"A1C and cardiovascular outcomes in type 2 diabetes: A nested case-control study","volume":"34","author":"Colayco","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0050","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.1630","article-title":"Association between serious ischemic cardiac outcomes and medications used to treat diabetes","volume":"17","author":"Margolis","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40261-013-0107-8","article-title":"Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy","volume":"33","author":"Barnett","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0065","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/dom.12020","article-title":"Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus","volume":"15","author":"Kothny","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0075","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1463-1326.2009.01124.x","article-title":"Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0085","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahr\u00e9n","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0090","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/jc.2008-2152","article-title":"Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes","volume":"94","author":"Ahr\u00e9n","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0095","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12284","article-title":"Glucagon dynamics during hypoglycaemia and food re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes","volume":"16","author":"Farngren","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0115","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-015-0215-2","article-title":"Cardiovascular safety of linagliptin in type 2 diabetes: A comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events","volume":"14","author":"Rosenstock","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0125","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2337\/dc12-2718","article-title":"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: A >\/=52-week randomized, double-blind study","volume":"36","author":"Yki-J\u00e4rvinen","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0135","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2337\/dc14-1684","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: A 52-week, randomized, double-blind clinical trial","volume":"38","author":"Laakso","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0145","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/459821","article-title":"The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus","volume":"2013","author":"Yousefzadeh","year":"2013","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-12-3","article-title":"Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: A pooled analysis","volume":"12","author":"Engel","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0155","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1463-1326.2010.01215.x","article-title":"Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population","volume":"12","author":"Schweizer","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0170","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0175","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0180","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/14746514040040040901","article-title":"Weight gain and insulin therapy","volume":"4","author":"Khan","year":"2004","journal-title":"Br J Diabetes Vasc Dis"},{"key":"10.1016\/j.jcjd.2015.06.010_bib0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/07315724.2003.10719316","article-title":"Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies","volume":"22","author":"Anderson","year":"2003","journal-title":"J Am Coll Nutr"},{"issue":"Suppl 2","key":"10.1016\/j.jcjd.2015.06.010_bib0195","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.2337\/dcS13-2018","article-title":"Is glucose control important for prevention of cardiovascular disease in diabetes?","volume":"36","author":"Mannucci","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267115005365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267115005365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:29:33Z","timestamp":1761492573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267115005365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1499267115005365"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2015.06.010","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2015.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}